1. To undertake clinical studies of radiotherapy with or without the administration of chemotherapeutic agent Cisplatin known to be radiosensitiser. 2. To perform pre-clinical studies of the radiosensitivity of human fibroblasts and cervix cancer cell lines in culture, with or without the addition of various HIV proteins or protease inhibitors, in order to determine the extent of any cellular radiosensitizing properties of these molecules. 3. To develop strategies for sensitising tumour cells to radiation, specifically by downregulating specific viral proteins that are known to be factors associated with resistance to radiotherapy

Condition	Intervention	Phase
Cancer of the Cervix	Procedure: Radiotherapy alone and Radiotherapy with Cisplatin	Phase III

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Female

Criteria

Inclusion Criteria: Cancer of the cervix, AIDS

Exclusion Criteria: unable to give an informed consent -

Please refer to this study by ClinicalTrials.gov identifier  NCT00122746

Branislav Jeremic, M.D., Ph.D.      +43-1-2600  Ext. 21666    b.jeremic@iaea.org

India
      Dr. Sarbani Ghosh Laskar, Dept. of Atomic Energy, TMC, Mumbai,  India; Recruiting

Study chairs or principal investigators

Branislav Jeremic, M.D., Ph.D.,  Study Director,  International Atomic Energy Agency   

Study ID Numbers:  E33022
Record last reviewed:  July 2005
Last Updated:  July 25, 2005
Record first received:  July 21, 2005
ClinicalTrials.gov Identifier:  NCT00122746
Health Authority: United Nations: International Atomic Energy Agency
ClinicalTrials.gov processed this record on 2005-07-26